Combination of Apigenin and Melatonin with nanostructured lipid carriers as anti-inflammatory ocular treatment DOI Creative Commons
Lorena Bonilla, Marta Espina, María L. García

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown, P. 125160 - 125160

Published: Dec. 1, 2024

Ocular inflammation is a complex pathology with limited treatment options. While traditional therapies have side effects, novel approaches, such as natural compounds like Apigenin (APG) and Melatonin (MEL) offer promising solutions. APG MEL, in combination nanostructured lipid carriers (NLC), may provide synergistic effect treating ocular inflammation, potentially improving patient outcomes reducing adverse effects. NLC could chemical protection of these compounds, while offering sustained release into the surface. Optimized exhibited suitable physicochemical parameters, physical stability, were biocompatible vitro corneal cell line, ovo by using hen's egg chorioallantoic membrane test. In vivo studies confirmed NLCs' ability to attenuate interleukin-6 (IL-6), IL-8 monocyte chemoattractant protein 1 (MCP-1) cytokine levels decreasing rabbit model. These findings suggest that co-encapsulation MEL represent strategy for managing inflammatory conditions.

Language: Английский

Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles DOI Creative Commons

Krisztina Bodnár,

Pálma Fehér,

Zoltán Ujhelyi

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(4), P. 449 - 449

Published: March 25, 2024

Psoriasis (PSO) is a chronic autoimmune skin condition characterized by the rapid and excessive growth of cells, which leads to formation thick, red, scaly patches on surface skin. These can be itchy painful, they may cause discomfort for patients affected this condition. Therapies psoriasis aim alleviate symptoms, reduce inflammation, slow down cell growth. Conventional topical treatment options are non-specific, have low efficacy associated with adverse effects, why researchers investigating different delivery mechanisms. A novel approach drug using nanoparticles (NPs) shows promise in reducing toxicity improving therapeutic efficacy. The unique properties NPs, such as their small size large area, make them attractive targeted delivery, enhanced stability, controlled release. In context PSO, NPs designed deliver active ingredients anti-inflammatory effect, immunosuppressants, or other compounds directly areas. formulations offer improved access epidermis facilitate better absorption, thus enhancing conventional anti-psoriatic drugs. increase surface-to-volume ratio, resulting penetration through skin, including intracellular, intercellular, trans-appendage routes. present review aims discuss latest approaches therapy PSO NPs. It intended summarize results vitro vivo examinations carried out last few years regarding effectiveness safety nanoparticles.

Language: Английский

Citations

13
Dermal Delivery of NanoFormulations: An Emerging Technology in Dermatological Conditions DOI

Mohee Shukla,

Satya Narain,

Ashwani Kumar

et al.

BioNanoScience, Journal Year: 2025, Volume and Issue: 15(2)

Published: Feb. 3, 2025

Language: Английский

Citations

1
Functional Polyphenol-Based Nanoparticles Boosted the Neuroprotective Effect of Riluzole for Acute Spinal Cord Injury DOI
Taoyang Yuan, Tianyou Wang, Jianhua Zhang

et al.

Biomacromolecules, Journal Year: 2024, Volume and Issue: 25(4), P. 2607 - 2620

Published: March 26, 2024

Riluzole is commonly used as a neuroprotective agent for treating traumatic spinal cord injury (SCI), which works by blocking the influx of sodium and calcium ions reducing glutamate activity. However, its clinical application limited because poor solubility, short half-life, potential organ toxicity, insufficient bioabilities toward upregulated inflammation oxidative stress levels. To address this issue, epigallocatechin gallate (EGCG), natural polyphenol, was employed to fabricate nanoparticles (NPs) with riluzole enhance effects. The resulting NPs demonstrated good biocompatibility, excellent antioxidative properties, promising regulation effects from M1 M2 macrophages. Furthermore, an in vivo SCI model successfully established, could be obviously aggregated at site. More interestingly, properties through regulating levels stress, inflammation, ion channels fully RNA sequencing sophisticated biochemistry evaluations. Together, work provided new opportunities design fabrication robust multifunctional inflammation-related diseases via biological integration polyphenols small-molecule drugs.

Language: Английский

Citations

5
Recent Advancements and Trends of Topical Drug Delivery Systems in Psoriasis: A Review and Bibliometric Analysis DOI Creative Commons
Pingyu An, Qiyue Zhao, Siyu Hao

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 7631 - 7671

Published: July 1, 2024

Abstract: Psoriasis is an immune-mediated inflammatory skin disease where topical therapy crucial. While various dosage forms have enhanced the efficacy of current treatments, their limited permeability and lack targeted delivery to dermis epidermis remain challenges. We reviewed evolution therapies for psoriasis conducted a bibliometric analysis from 1993 2023 using predictive linear regression model. This included comprehensive statistical visual evaluation each model's validity, literature profiles, citation patterns, collaborations, assessing R variance mean squared error (MSE). Furthermore, we detailed structural features penetration pathways emerging drug systems treatment, such as lipid-based, polymer-based, metallic nanocarriers, nanocrystals, highlighting advantages. systematic overview indicates that future research should focus on developing novel characterized by stability, biocompatibility, drug-carrying capacity. Keywords: psoriasis, bibliometric, delivery, nanoparticle, nanocarriers

Language: Английский

Citations

4
Novel Tissue-Specific Multifunctionalized Nanotechnological Platform Encapsulating Riluzole Against Motor Neuron Diseases DOI Creative Commons
Gerard Esteruelas, Miren Ettcheto, Isabel Haro

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2273 - 2288

Published: Feb. 1, 2025

Motor neuron diseases are neurological disorders characterized by progressive degeneration of upper and/or lower motor neurons. Amyotrophic Lateral Sclerosis (ALS) is the most common form diseases, where patients suffer paralysis, muscle atrophy and finally death. Despite ALS severity, no treatment safe fully effective. In this area, Riluzole was first drug approved it constitutes gold-standard for pathology. However, to obtain suitable therapeutic efficacy, requires high doses that associated with severe adverse effects in other tissues. To attain efficacy avoiding organs side-effects, new strategies enhance delivery specifically neurons constitute an unmet medical need. we have developed a novel multifunctional nanostructurated carrier selectively deliver This work develops characterizes at vitro vivo levels tissue-targeted formulation peptide PEG-labelled PLGA nanoparticles encapsulating Riluzole. For purpose, pVEC, cell penetrating able increase transport through blood-brain barrier, attached surface. The multifunctionalized show characteristics release central nervous system were detected within 1 h after administration while significantly reducing concentration non-therapeutic responsible side effects. A has been characterized, demonstrating enhanced CNS biodistribution riluzole, which shows promise as efficient tool including amyotrophic lateral sclerosis.

Language: Английский

Citations

0
Synthesis and characterization of protein nanohybrid systems for the brain delivery of Riluzole DOI

Ujjwal Gupta,

Amit Kumar,

Md Imtiyaz Alam

et al.

Therapeutic Delivery, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 11

Published: March 24, 2025

Aims Synthesis and Characterization of Protein NanoHybrid Systems for the Brain Delivery Riluzole.

Language: Английский

Citations

0
Controlled release of deferiprone using iron-responsive nanoparticles integrated with dissolving microneedle for novel alternative treatments of β-thalassemia major DOI

Muh. Taufik Hidayat,

Sitti Nur Khadijah Maharani,

Indianty Dwi Ramadhany

et al.

European Journal of Pharmaceutics and Biopharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 114702 - 114702

Published: March 1, 2025

Language: Английский

Citations

0
Development and Evaluation of Docetaxel-Loaded Nanostructured Lipid Carriers for Skin Cancer Therapy DOI Creative Commons

Florentina-Iuliana Cocoș,

Valentina Anuţa, Lăcrămioara Popa

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(7), P. 960 - 960

Published: July 19, 2024

This study focuses on the design, characterization, and optimization of nanostructured lipid carriers (NLCs) loaded with docetaxel for treatment skin cancer. Employing a systematic formulation development process guided by Design Experiments (DoE) principles, key parameters such as particle size, polydispersity index (PDI), zeta potential, entrapment efficiency were optimized to ensure stability drug-loading efficacy NLCs. Combined XRD cryo-TEM analysis employed NLC nanostructure evaluation, confirming formation well-defined nanostructures. In vitro kinetics studies demonstrated controlled sustained release over 48 h, emphasizing potential prolonged therapeutic effects. Cytotoxicity assays human umbilical vein endothelial cells (HUVEC) SK-MEL-24 melanoma cell line revealed enhanced against cancer cells, significant selective cytotoxicity minimal impact normal cells. multidimensional approach, encompassing comprehensive positions docetaxel-loaded NLCs promising candidates advanced therapy. The findings underscore translational these nanocarriers, paving way future preclinical investigations clinical applications in treatment.

Language: Английский

Citations

2
Antitumoral melatonin-loaded nanostructured lipid carriers DOI
Lorena Bonilla, Marta Świtalska, Marta Espina

et al.

Nanomedicine, Journal Year: 2024, Volume and Issue: 19(23), P. 1879 - 1894

Published: Aug. 2, 2024

Aim: Cancer constitutes the second leading cause of death worldwide, with conventional therapies limited by significant side effects. Melatonin (MEL), a natural compound antitumoral properties, suffers from instability and low solubility. To overcome these issues, MEL was encapsulated into nanostructured lipid carriers (MEL-NLC) containing rosehip oil to enhance stability boost its activity. Methods: MEL-NLC were optimized design experiments approach characterized for their physicochemical properties. Stability biopharmaceutical behavior assessed, along interaction studies in vitro efficacy against various cancer cell lines. Results: Optimized exhibited desirable characteristics, including small particle size sustained release, long-term stability. In demonstrated that selectively induced cytotoxicity several lines while sparing healthy cells. Conclusion: represent promising alternative cancer, combining enhanced targeted activity, potentially overcoming limitations treatments.

Language: Английский

Citations

2
Melatonin loaded nanostructured lipid carriers for the treatment of uveal melanoma DOI Creative Commons
Lorena Bonilla, Marta Espina, María L. García

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 100, P. 106057 - 106057

Published: Aug. 10, 2024

Uveal melanoma, a highly aggressive intraocular tumor and the second most common form of ocular malignancy, currently lacks effective therapeutic options. Therefore, this study addresses an unmet medical need by developing nanostructured lipid carriers (NLC) as potential delivery system for melatonin (MEL) to target uveal melanoma. NLC were optimized ophthalmic administration addition cationic surfactant increase mucoadhesivity negatively charged surface. MEL-loaded (MEL-NLC) exhibited suitable particle size (<200 nm), good colloidal stability (5 months), sustained MEL release. In vitro cytotoxicity assays demonstrated antiproliferative activity against melanoma cells while maintaining corneal cell viability, further confirmed in HET-CAM test vivo tolerance studies. Additionally, inflammation studies performed since constitutes one main hallmarks cancer development progression. Consequently, MEL-NLC displayed anti-inflammatory properties. Furthermore, preliminary biodistribution results suggested their ability reach posterior segment eye, mainly retina ciliary body, positioning them promising strategy treatment.

Language: Английский

Citations

2